Wave Life Sciences (WVE) Soars to 6-Year High on Obesity Drug Clinical Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Wave Life Sciences Ltd (NASDAQ:WVE) is one of the best performers on Monday.

Wave Life hit a new six-year high on Monday after soaring by more than double following stellar results from the first phase of its obesity drug clinical trial.

At intra-day trading, the stock climbed to its highest price of $19.54 before trimming gains to finish the day just up by 147.26 percent at $18.52 apiece.

Sergey Nivens/Shutterstock.com

In an updated report, Wave Life Sciences Ltd (NASDAQ:WVE) said that enrolled patients who took 240 mg of its drug candidate, WVE-007, improved their body composition through a 4.5 percent total fat loss, 9.4 percent visceral fat reduction, and a 3.2 percent increase in lean mass in just three months.

Notably, the drug candidate taken up to 600 mg was generally safe and well-tolerated, and there were no serious adverse events recorded.

Wave Life Sciences Ltd (NASDAQ:WVE) expects to deliver the results of the second round of the clinical trial, covering six months for the 240 mg single-dose cohort, as well as three-month follow-up data for the 400mg single-dose cohort.

In the second quarter of 2026, the company is also targeting to deliver six-month follow-up data from the 400 mg single-dose cohort and three-month follow-up data from the 600 mg single-dose cohort.

For phase 2, Wave Life Sciences Ltd (NASDAQ:WVE) would evaluate WVE-007 as both a monotherapy and an add-on therapy to incretins in populations with higher BMI and related co-morbidities, and as a maintenance therapy post-incretin treatment.

While we acknowledge the risk and potential of WVE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WVE and that has 10,000% upside potential, check out our report about this cheapest AI stock.